Both in Pharmaceuticals
Upstream Bio vs Evommune
Over the past year UPB returned −88.3% and EVMN returned −74.4%; their daily moves had a correlation of 0.13.
UPB −88.3% EVMN −74.4%Growth of $1, one year, split-adjusted
| Metric | UPB | EVMN |
|---|---|---|
| Price | $2.76 | $5.17 |
| Market cap | $151.2M | $187.6M |
| Today | −18.10% | −12.82% |
| 1 month | −48.0% | −44.8% |
| 6 months | −72.4% | −81.2% |
| Year to date | −89.8% | −69.8% |
| 1 year | −87.3% | — |
| Revenue growth (YoY) | −17.5% | — |
| Gross margin | 100.0% | — |
| Net margin | −5136.1% | — |
| P/E (TTM) | — | — |
| Price / sales | 47.9× | — |
| Net cash | $261.3M | $200.4M |
| Dividend yield | — | — |
| Volatility (60d) | 76.9% | 77.1% |
| Short % of float | 13.3% | 13.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).